High Throughput Isolation Of T Cells For The Treatment Of Metastatic Cancer
Background:
The National Cancer Institute's Surgery Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize high throughput T cell isolation technology.
Technology:
The adoptive transfer of autologous antigen reactive lymphocytes
has been shown to mediate significant tumor regression in some
patients with metastatic cancer. However, the isolation of
these T lymphocytes typically requires invasive surgery, which can
lead to post-operative complications and delays in initiating
adoptive immunotherapy with T cells.
This technology is directed to the use of a novel high throughput
technique to isolate highly enriched tumor reactive lymphocytes in
a non-invasive manner from the peripheral blood of cancer
patients. The isolated T lymphocytes can be used in adoptive
immunotherapy for the treatment of metastatic cancer. The
technique is rapid, easy to use, and utilizes a highly sensitive
PCR based screening assay. The method can detect the presence
of extremely rare T cells in a bulk population of peripheral blood
cells.
Further R&D Needed:
- Robotic Automation to enhance throughput of T cell isolation
and cloning
- Isolation of virus specific T cells for potential anti-viral
therapy
R&D Status: Method validated using
peripheral blood of cancer patients.
IP Status:
- U.S. Patent Application No. 61/027,623 filed 11 Feb 2008
Value Proposition:
- Rapid, easy to use, non-surgical technique utilizes a highly
sensitive PCR based screening assay for isolating tumor reactive T
cells
- Method can detect the presence of extremely rare T cells in a
bulk population of peripheral blood cells.
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #788
Revised 12/8/2008